Added to chemotherapy, this drug doubles lung cancer survival – Medical News Today
Medical News Today |
Added to chemotherapy, this drug doubles lung cancer survival
Medical News Today The new phase III clinical trial demonstrated that adding the immunotherapy drug pembrolizumab to chemotherapy doubled survival in people with metastatic nonsquamous non-small cell lung cancer (NSCLC) and no mutations in the epidermal growth factor … |
